44.03 Pilot Study of SAVI SCOUT® to Localize Non-Palpable Breast Lesions to Reduce Re-excision

R. Shirley1, P. Peddi1, S. Ahmed1, Q. D. Chu1  1Louisiana State University Health Sciences Center-Shreveport,Surgery,Shreveport, LA, USA

Introduction: Wire localization (WL) is standard preoperative procedure to localize non-palpable breast lesions.  The SAVI SCOUT® guidance system is an FDA-approved medical device that uses non-radioactive electromagnetic wave technology and serves as an alternate to WL technique.  The purpose of the study is to compare the re-excision rates between WL and SAVI SCOUT® and assess the ease of performing such a technique by surgical trainees.   

Methods: We performed an IRB approved retrospective chart review of all women undergoing WL from 2011-2015 and compared them to women undergoing SAVI SCOUT® technique from 2015-2016. Re-excision rates, weights of the final specimens, and rate of detection by surgical trainees were calculated. Statistical t-tests and chi square tests were used.  P-value ≤0.05 was considered as statistically significant. 

Results:Of the 116 WL breast cancer biopsies performed, 43 required re-excision (37%).  Of the 26 SAVI SCOUT® performed, 17 were malignant; of these 17, only 2 required re-excision (11.8%; P=0.04).  This translates to a reduction of 68.2% with SAVI SCOUT®.  The average specimen weight for the WL group was 63g versus 55g for the SAVI SCOUT® group (P=0.38.  The average margin width was 2.7 mm for the WL versus 3.0mm for the SAVI SCOUT® (P=0.43). Surgical residents were successful in localizing the lesions in 25 out of 26 (96%) patients using SAVI SCOUT® technique.   

Conclusion:The re-excision rate was significantly lower with SAVI SCOUT® and can easily be done by surgical residents. Given its advantages, SAVI SCOUT® should be considered over WL technique.